Lung Cancer
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If Lung Cancer is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- GenFleet's KRAS G12D Lung Cancer Drug Shows Strong Phase II Results, Advancing to First Global Phase III Trial · TipRanks · 2026-09-21
- Association of tumor mutational burden and tumor-infiltrating lymphocytes with second primary cancer after complete resection of non-small cell lung cancer · Frontiers Precision Oncology · 2026-09-17
- Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRASG12C mutations. · Future Oncol · 2026-09-16
- AI Tool Outperforms PD-L1 for Predicting Lung Cancer Immunotherapy Outcomes · Inside Precision Medicine · 2026-09-15
- Resistance to Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators · Journal of Clinical Oncology · 2026-09-14
- AbbVie’s Bet on Biology: Why One Modality Is Never Enough in Lung Cancer · The Clinical Trial Vanguard · 2026-09-21 · usually covers Auto
What the reporting says
It shows up alongside Immunotherapy (64), KRAS (63 — acquisition ×2), Overall Survival (48), Colorectal Cancer (43), Egfr (39), Breast Cancer (37), Her2 (23), FDA (40).
Two steps out: MSI-H (through Immunotherapy, 54 shared stories on the weaker link); Pancreatic Cancer (through KRAS, 49 shared stories on the weaker link); KRAS Mutant (through KRAS, 45 shared stories on the weaker link); AI (through Immunotherapy, 43 shared stories on the weaker link).
Tracked since Jan 1, with coverage on 69 separate days — concentrated in Oncology and Pubmed Targeted.